Anterogen Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • 065660

Stock Symbol

  • Share Price
  • $14.78
  • (As of Friday Closing)

Anterogen General Information

Description

Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Contact Information

Website
www.anterogen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 345-30 Gasan-dong
  • Geumcheon-gu
  • Seoul, 08589
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Corporate Office
  • 345-30 Gasan-dong
  • Geumcheon-gu
  • Seoul, 08589
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anterogen Stock Performance

As of 20-Jun-2025, Anterogen’s stock price is $14.78. Its current market cap is $148M with 10M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.78 $14.81 $9.64 - $17.73 $148M 10M 21.6K -$0.18

Anterogen Financials Summary

As of 31-Mar-2025, Anterogen has a trailing 12-month revenue of $5.02M.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 98,397 97,878 99,166 82,350
Revenue 5,020 5,081 4,972 5,101
EBITDA (2,394) (2,260) (1,884) (4,166)
Net Income (1,736) (1,680) (2,173) (5,291)
Total Assets 65,361 78,806 115,957 98,291
Total Debt 0 0 7,558 10,065
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Anterogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anterogen‘s full profile, request access.

Request a free trial

Anterogen Patents

  • 78

    Total Documents Applications and Grants

  • Total Patents Families

  • 44

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Anterogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025507128-A Method for producing stem cell culture medium with increased growth factor content using a double crosslinked hydrogel scaffold and composition obtained therefrom Pending 08-Mar-2022
US-20230167143-A1 Prodrugs of l-bhdu and methods of treating viral infections Active 29-Oct-2021
US-11945833-B2 Prodrugs of l-bhdu and methods of treating viral infections Active 29-Oct-2021
CA-3235899-A1 Prodrugs of l-bhdu and methods of treating viral infections Pending 29-Oct-2021
EP-4423100-A1 Prodrugs of l-bhdu and methods of treating viral infections Pending 29-Oct-2021 C07F9/65586
To view Anterogen’s complete patent history, request access »

Anterogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anterogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Anterogen‘s full profile, request access.

Request a free trial

Anterogen ESG

Risk Overview

Risk Rating

Updated May, 18, 2022

30.75 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view Anterogen’s complete esg history, request access »

Anterogen FAQs

  • When was Anterogen founded?

    Anterogen was founded in 2000.

  • Where is Anterogen headquartered?

    Anterogen is headquartered in Seoul, South Korea.

  • What is the size of Anterogen?

    Anterogen has 29 total employees.

  • What industry is Anterogen in?

    Anterogen’s primary industry is Biotechnology.

  • Is Anterogen a private or public company?

    Anterogen is a Public company.

  • What is Anterogen’s stock symbol?

    The ticker symbol for Anterogen is 065660.

  • What is the current stock price of Anterogen?

    As of 20-Jun-2025 the stock price of Anterogen is $14.78.

  • What is the current market cap of Anterogen?

    The current market capitalization of Anterogen is $148M.

  • What is Anterogen’s current revenue?

    The trailing twelve month revenue for Anterogen is $5.02M.

  • What is Anterogen’s annual earnings per share (EPS)?

    Anterogen’s EPS for 12 months was -$0.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »